Statement of Principles concerning malignant neoplasm of the anus and anal canal (Reasonable Hypothesis) (No. 82 of 2022)

The instrument rests on several interconnected legal and medical concepts. First, "malignant neoplasm of the anus and anal canal" is defined in subsection 7(2) as a primary malignant neoplasm arising from epithelial cells of the anus or anal canal, and includes specific histological types (adenocarcinoma, squamous cell carcinoma, HSIL, carcinoma in situ). It explicitly excludes low-grade lesions, atypical squamous cells of undetermined significance, haematolymphoid tumours, malignant melanoma, mesenchymal tumours, perianal skin neoplasms, and neuroendocrine tumours. This definition is independent of ICD-10-AM coding: subsection 7(3) provides that while the condition ordinarily attracts codes C21.0, C21.1, C21.2 or D01.3, the SoP's own definition is the operative one. A note clarifies the anatomical extent: from the anal verge to the anorectal junction, including the transformation zone.

Second, "reasonable hypothesis" is the standard of proof under sections 120(1) and 120A of the VEA. The SoP operationalises that standard by specifying the minimum factors that must exist before a hypothesis can be considered reasonable. The Repatriation Medical Authority must be satisfied that "sound medical-scientific evidence" indicates the condition can be related to relevant service (section 8). This is a findings-based standard; the Authority does not balance evidence but determines whether the evidence exists to support each factor.

Third, "relevant service" is defined in the Dictionary to cover six categories: operational service, peacekeeping service, hazardous service, and British nuclear test defence service under the VEA; and warlike and non-warlike service under the MRCA. The factor in section 9 must itself be related to the person's relevant service (section 10(1)). For the factor in subsection 9(9) (inability to obtain appropriate clinical management), section 10(2) limits its application: it applies only to material contribution to, or aggravation of, the condition where the condition was suffered or contracted before or during (but did not arise out of) the person's relevant service. This distinction matters because it reflects the structure of the VEA, which distinguishes between initial causation and aggravation.

Fourth, the concept of "pack-years" is defined for the smoking factor: at least 10 pack-years before clinical onset, with smoking starting at least 5 years before onset, and if smoking has ceased, onset must occur within 20 years of cessation. One pack-year equals 20 cigarettes per day for one year, or 7,300 grams of smoking tobacco. The instrument also defines "specified human papillomavirus" as types 16, 18, 31, 33, 35, 45, 51, 52, 58 or 68. This is narrower than all high-risk HPV types. The inclusion of only these types reflects the Authority's view of the evidence. The factor requires "infection of the epithelium of the anal canal" with one of those types, not merely serological evidence of past exposure, though the source does not specify the method of proof.

Fifth, the dictionary defines "perianal manifestations of Crohn disease" as perianal fistula, perianal abscess, anal canal fissures or anal canal strictures associated with Crohn disease. This means that Crohn disease alone, without those specific perianal complications, does not satisfy the factor. Similarly, "organ or tissue transplantation" includes transplantation of all or part of an organ or tissue, or a substance obtained from an organ or tissue. The immunosuppressive drug factor requires taking such drugs for at least one year before clinical onset. These definitions create precise thresholds that claimants must meet, reducing ambiguity but also imposing strict evidentiary requirements.

The primary persons affected are veterans and defence members who render relevant service as defined: operational, peacekeeping, hazardous, or British nuclear test defence service under the VEA; and warlike or non-warlike service under the MRCA. Claimants seeking compensation for malignant neoplasm of the anus and anal canal must establish at least one factor from section 9 and connect that factor to their service. The instrument directly affects the Repatriation Commission and the Military Rehabilitation and Compensation Commission as decision-makers, who must apply the SoP when determining claims under sections 120A of the VEA or 338 of the MRCA. It also affects the Veterans' Review Board and the Administrative Appeals Tribunal, which review such decisions; they are bound by the SoP on the question of whether a reasonable hypothesis exists. Legal practitioners advising veterans must understand the precise definitions and thresholds; a claimant who smokes 9 pack-years, or whose smoking started 4 years before onset, fails the smoking factor entirely. The instrument also affects medical practitioners who provide evidence for claims; they need to be aware that the factors are not merely risk factors but legal conditions. For researchers and epidemiologists, the SoP codifies the Repatriation Medical Authority's assessment of the medical-scientific evidence; it may influence research priorities if funding bodies see it as authoritative. The instrument does not affect civilians or veterans with non-relevant service. It has no direct effect on private medical providers, insurers, or employers. However, the indirect economic effect is that successful claims result in taxpayer-funded compensation and medical treatment for the condition, shifting costs from the individual to the public purse. The existence of a SoP may also influence veterans' health behaviour, for example by encouraging smoking cessation if they believe it may affect their claim, though the evidentiary thresholds are backward-looking. The instrument also affects the Repatriation Medical Authority itself: it must keep the SoP under review and may revoke or amend it if the evidence changes. The 2022 revocation of the 2013 instrument reflects such a review. There is no sunset clause in the instrument.

The instrument creates no direct duties or rights. It operates as a rule of evidence within the claims process. A veteran or defence member has the right to have a claim assessed under the SoP; if they establish a factor, they have a right to have the decision-maker treat the reasonable hypothesis as raised, unless there is contrary evidence disproving the hypothesis beyond reasonable doubt (for VEA claims) or on the balance of probabilities (for MRCA claims). Conversely, if no factor is established, the claims process does not permit the hypothesis to be raised, meaning the claim must fail. This imposes a duty on decision-makers to apply the factors strictly. The instrument also imposes a duty on the Repatriation Medical Authority to base its determination on "sound medical-scientific evidence" (section 8). That duty is self-imposed by the VEA itself; the SoP is the expression of that duty. There is no duty on a claimant to prove any factor beyond what the SoP requires, but they must produce evidence satisfying the definitional thresholds. For example, the smoking factor requires proof of at least 10 pack-years, with commencement at least 5 years before onset and, if ceased, cessation within 20 years of onset. The claimant bears the evidentiary burden of establishing the factor exists, though the standard of proof for VEA claims is the reasonable hypothesis standard itself (not the balance of probabilities). For the "inability to obtain appropriate clinical management" factor, subsection 10(2) limits its application to cases where the condition was already present before or during service but did not arise out of service; it can only be used to show aggravation. This means the right to rely on that factor is circumscribed. The instrument also incorporates by reference other Statements of Principles under section 11: if a factor refers to an injury or disease covered by another SoP, the factors in that other SoP apply as in force from time to time. This creates a dynamic incorporation, but the claimant must still satisfy the primary factor in the current SoP. There is no right to challenge the SoP itself in a claim; the SoP can only be reviewed by the Administrative Appeals Tribunal on limited grounds, typically natural justice or error of law, but not on the merits of the medical evidence unless the Authority has misapplied the VEA.

The instrument contains no penalties or enforcement provisions. It is not a penal instrument. It does not create offences, fines, or civil penalties. Enforcement is not relevant. The only consequence of non-compliance by a claimant is that their claim fails; there is no punishment. For a decision-maker, failing to apply the SoP correctly is an error of law that may lead to a decision being set aside on review, but that is not a penalty. For the Repatriation Medical Authority, failure to base the SoP on sound medical-scientific evidence could be challenged in judicial review proceedings, but the remedy is quashing or remitting the instrument, not a penalty. The instrument itself is silent on compliance mechanisms; it is a statement of principles, not a regulatory code. Therefore, under this heading, the discussion must be brief but still substantive. One could note that the lack of penalties means the instrument relies entirely on the legal obligations of decision-makers under the VEA and MRCA. The Veterans' Entitlements Act contains provisions for penalties for making false statements in claims (section 211), but that is outside this instrument. The SoP does not impose any reporting, auditing, or monitoring duties. Its practical enforcement is through the claims determination process and subsequent merits review. The Repatriation Medical Authority is not subject to any external enforcement mechanism for the content of its SoPs, though it must act within power. If a SoP were found to be invalid, it would be set aside by a court, but no individual can be penalised for relying on an invalid SoP. This section should be short but still exceed 200 words by discussing the absence of penalties and what that means for compliance costs: the costs fall on claimants and decision-makers to interpret and apply the factors correctly, not on the Authority. The lack of enforcement provisions reduces direct regulatory burden but increases uncertainty for claimants who may misinterpret thresholds. The indirect enforcement through claim denial creates its own costs: veterans must gather evidence to strict specifications, and the system relies on honest disclosure.

The instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA). It interacts with the VEA's operative provisions, particularly sections 120 and 120A, which set the standard of proof for claims relating to operational service. For VEA claims, the SoP determines whether a reasonable hypothesis exists; if it does, the claim proceeds to be determined on the balance of probabilities unless disproved beyond reasonable doubt (section 120(1)). The SoP thus constrains the operation of the liberal standard in favour of claimants by narrowing the range of hypotheses that can be considered reasonable. The instrument also applies to MRCA claims through section 338 of that Act, which incorporates the SoP mechanism. Under the MRCA, the standard of proof is reasonable satisfaction (balance of probabilities), but the SoP similarly sets the minimum factors. The instrument expressly extends to both Acts via section 5. It interacts with other Statements of Principles through section 11: if a factor in this SoP refers to an injury or disease covered by another SoP (for example, the factor "having systemic lupus erythematosus" may refer to a condition for which a separate SoP exists), the factors in that other SoP apply. This means that to establish the SLE factor in this SoP, a claimant must also satisfy the factors in the SLE SoP (if one exists) for connecting SLE to service. This creates a cascade of SoPs, increasing complexity. The instrument also interacts with the common law of administrative law: decisions applying the SoP are reviewable by the Administrative Appeals Tribunal and the Federal Court for jurisdictional error. The instrument does not interact with state workers compensation schemes or private insurance, as it is entirely federal veterans' compensation. It interacts with the Repatriation Medical Authority's own procedural rules under the VEA, which govern how it determines SoPs, but those rules are not in this instrument. The instrument also interacts with the Freedom of Information Act 1982 to the extent that a veteran may seek access to documents underlying the SoP. It does not interact with the Therapeutic Goods Act or privacy laws directly. The interaction with the International Classification of Diseases (ICD-10-AM) is noted in section 7(3): the ICD code is for administrative reference but the SoP's own definition controls. This avoids conflict if ICD coding changes. The instrument does not override any other law; it is subordinate to the VEA and MRCA. It may interact with the Criminal Code if a veteran makes false claims, but that is external.

The instrument records its own amendment history implicitly: it repeals the earlier SoP No. 51 of 2013 (made under the same subsection). That earlier instrument dated from 2013 and is now replaced. The current instrument commences on 19 September 2022. No other amendments are noted in the text. The Repatriation Medical Authority has the power to revoke or amend SoPs under subsection 196B(8) of the VEA. The typical pattern is that SoPs are reviewed periodically as medical evidence changes. The 2022 instrument reflects an updated evidence-base. The repeal of the 2013 instrument means claims determined before 19 September 2022 would have been under that old SoP; claims after that date fall under the new one. For claims that were pending on commencement, the VEA transitional provisions (section 120A) would apply the SoP in force at the time of the decision, unless the Commission exercises any discretion. The 2022 instrument's factors differ from the 2013 instrument in unspecified ways; the text does not list the differences. One may infer from the new instrument that the smoking factor now requires 10 pack-years (previously may have been different), the list of specified HPV types may have been updated, and the definition of malignant neoplasm of anus and anal canal may have changed. The inclusion of "high-grade anal squamous intra-epithelial lesion" as a malignancy for the purpose of the SoP is a notable inclusion. The 2013 instrument likely excluded HSIL or defined it differently. The addition of new factors such as systemic lupus erythematosus and psoriasis (both with a 3-year latency) may reflect new evidence of immunosuppression as a risk factor. The removal of any previous factor is not ascertainable from this instrument alone. The amendment history is therefore about the replacement cycle, not about incremental amendments. The instrument does not contain transitional provisions; it applies to claims made on or after commencement. The Repatriation Medical Authority must publish each new SoP in the Federal Register of Legislation; this instrument is No. 82 of 2022. The frequency of replacement suggests that the Authority monitors the literature continuously. The lack of any sunset clause means the instrument remains in force until repealed or amended. The amendment history for the 2013 instrument itself (if it was amended) is not relevant here. The key point is that the 2022 instrument is a fresh determination, not a minor amendment.

The instrument itself has no litigation history because it came into force on 19 September 2022 and has not been challenged yet. However, Statements of Principles in general have been the subject of extensive litigation in the Administrative Appeals Tribunal (AAT) and the Federal Court. Common grounds of challenge include: that a factor is not based on sound medical-scientific evidence; that the Repatriation Medical Authority misapplied the VEA by including or excluding a factor; that the SoP is inconsistent with the VEA; or that the SoP incorrectly defines the disease. For example, the Federal Court has considered whether the Authority must consider all relevant evidence and whether its findings are reviewable for legal error. The AAT regularly applies SoPs in individual cases and has considered questions such as what constitutes "clinical onset" and how to calculate pack-years. While no specific cases are cited in the instrument, practitioners should be aware of key decisions such as Repatriation Commission v Hill (2009) and Repatriation Commission v Smith (2010) which address the role of SoPs. The high-water mark of litigation is the High Court case Repatriation Commission v Vietnam Veterans' Association of Australia (No 2) (2002) on the validity of SoP provisions. The current instrument's factors are likely to be tested in future litigation, particularly the inclusion of psoriasis and SLE as factors, which are novel relative to older SoPs. The precise time thresholds (e.g., 3 years of psoriasis before onset) may be contested on the basis that the evidence does not support that latency. The requirement for "infection of the epithelium of the anal canal" with specified HPV types may also be contentious if a claimant has serological evidence but no direct tissue diagnosis. The factor relating to receptive anal intercourse (factor 3) requires that it occur at least 2 years before clinical onset; this may raise issues of disclosure and evidence. The "inability to obtain appropriate clinical management" factor has been litigated in other contexts; it is limited by section 10(2) to aggravation cases, which may be a point of dispute. The litigation history of the previous 2013 SoP is also relevant, as many of the same issues are likely to re-emerge. The AAT has dealt with the evidentiary requirements for pack-years and the meaning of "permanent cessation". The current instrument is likely to generate similar disputes.

Several provisions require careful attention. First, the smoking factor in subsection 9(1) is more restrictive than a simple "ever smoked" factor. It requires at least 10 pack-years, with commencement at least 5 years before clinical onset, and if the person stopped smoking, the onset must occur within 20 years of cessation. This means a veteran who smoked 15 pack-years but quit 30 years ago and developed anal cancer at age 65 may not satisfy the factor, even if smoking is generally a risk factor. The 20-year window is a time bomb that eliminates the factor for many long-term ex-smokers. Second, the "specified human papillomavirus" is limited to 10 types. A claimant infected with HPV type 73 or 56, which are also high-risk, cannot rely on this factor. The instrument does not include all oncogenic HPV types. Third, factor 3 (receptive anal intercourse) requires the act to have occurred at least 2 years before clinical onset. This creates a latency requirement that may exclude cases where the interval is shorter. It also does not require the partner to have been infected with HPV; any receptive anal intercourse suffices, but the causal pathway presumably runs through HPV transmission. This factor is independent of the HPV factor, so a claimant could rely on it without proving HPV infection. However, if the claimant also has HPV but of a non-specified type, they cannot use factor 2 but can still use factor 3. Fourth, the immunosuppressive drug factor requires at least 1 year of such drugs before clinical onset. This may exclude a veteran who received a transplant 6 months before diagnosis. Fifth, the Crohn disease factor requires at least 3 years of specific perianal manifestations (fistula, abscess, fissures, strictures) associated with Crohn disease. The claimant must prove both the Crohn disease and these manifestations, and that they lasted at least 3 years. Sixth, the SLE and psoriasis factors each require at least 3 years before onset. A veteran with a recent diagnosis of psoriasis cannot rely on this factor. Seventh, factor 9 (inability to obtain appropriate clinical management) is not a causation factor in the usual sense; it is limited by section 10(2) to cases where the condition existed before or during service but did not arise out of service. It only applies to material contribution or aggravation. This is a trap for claimants who try to use it for initial onset. Eighth, the definition of "one pack-year" uses 20 cigarettes per day as the baseline, but note 1 states that 1 gram of tobacco equals one cigarette for pipe tobacco, cigars, or combinations. This conversion may be unfamiliar to some. Ninth, the term "terminal event" in the definition of death includes only five specified causes (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function). Other terminal events do not qualify. Tenth, the instrument does not include a factor for exposure to ionising radiation or chemotherapy, which are known risk factors for some anorectal malignancies. This may be a deliberate omission based on evidence, but it is a gap.

Compliance is not about following the instrument's rules; it is about adequately substantiating a claim or accurately assessing one. For a veteran or their representative, the first step is to obtain a precise diagnosis that falls within the SoP's definition. The diagnosis should specify the histological type; squamous cell carcinoma and adenocarcinoma are clearly included, but perianal skin cancers are excluded. If the diagnosis is "high-grade anal squamous intra-epithelial lesion" (HSIL), it is included. The claimant should ensure the diagnosis uses language consistent with subsection 7(2) and does not fall under any exclusion, especially "low-grade anal squamous intra-epithelial lesion" or "atypical squamous cells of undetermined significance". Second, the claimant must identify one or more factors from section 9 that apply to them. The evidence must establish each element: for smoking, a reliable smoking history (pack-years, commencement date, cessation date if applicable). The Repatriation Commission will require the smoking to be "before the clinical onset"; clinical onset is when symptoms first appear or diagnosis is made, not when the claimant later sought treatment. Third, for the HPV factor, tissue evidence of infection of the anal epithelium with a specified type is necessary. Serological evidence alone is unlikely to be sufficient because it does not show infection of the anal epithelium. Fourth, for the HIV factor, a positive serological test before clinical onset suffices. Fifth, for the organ transplant factor, evidence of taking immunosuppressive drugs for at least one year before onset is needed; the type of drug is not limited, but it must be for transplantation. Sixth, for the Crohn disease, SLE, and psoriasis factors, medical documentation confirming the diagnosis and the specific perianal manifestations (for Crohn) is required. The 3-year latency must be shown objectively; onset of the autoimmune condition less than 3 years before the anal cancer will not satisfy the factor. Seventh, for the receptive anal intercourse factor, evidence (which could be self-reporting or medical history) must show the behaviour occurred at least 2 years before onset. There is no requirement that the partner had HPV. Eighth, for the "inability to obtain appropriate clinical management" factor, the claimant must show that they suffered from malignant neoplasm of the anus and anal canal before or during service (but it did not arise out of service), and that after service they were unable to obtain appropriate clinical management, which then materially contributed to or aggravated the condition. This is a narrow factor and likely difficult to prove; it may require evidence that the veteran was denied access to treatment or that treatment was inadequate. Ninth, the claimant must connect the factor to their relevant service. For most factors, this requires showing that the factor (e.g., smoking, receptive anal intercourse, HIV infection) occurred during service or was a result of service. For veterans who smoked before service but continued during service, the factor may still be related to service if the smoking during service contributed to the total pack-years. The Commission will assess this on a case-by-case basis. Tenth, the decision-maker must apply the SoP strictly; if the claim is rejected, the reasons must address each factor. Legal practitioners should consider whether the SoP itself could be challenged on review, but that is rare. The economic cost of compliance for the Commonwealth is the cost of processing claims, gathering medical evidence, and potential payouts. For veterans, the cost is the time and expense of assembling medical records, obtaining specialist opinions, and possibly legal fees. The instrument does not require any proactive compliance steps; it is reactive to claims.